May Orfali, MD, MBA

Oncology Medical

Dr. May Orfali has a deep and extensive background in clinical drug development and regulatory strategy that spans over two decades in multiple therapeutic areas, with a focus on rare diseases, gene therapy, CAR-T, oncology, hematology, infectious disease, and women’s health. Prior to her current role of President at Rare disease & Oncology Consulting, LLC, she was the chief medical officer at CANbridge Life Sciences where she led the clinical development and medical affairs group, focused on progressing phase 1 and phase II oncology assets in glioblastoma multiforme and esophageal cancer, filing NDA for neratinib in china in adjuvant and metastatic breast cancer therapy, in addition to leading medical review of business development opportunities in rare disease space. Prior to that, she was Executive Director, Global Product Development, Pfizer, Inc., USA, where she was responsible for patient-focused drug development across multiple rare disease assets in hematology, sickle cell disease, hemophilia, endocrinology, gene therapy and TTR-amyloidosis. Prior to that role, Dr. Orfali was Senior Director and Global Medical Lead/Medicines Development Group, Specialty Care Business Unit, Pfizer, where she was responsible for developing rare disease drug development strategy, including gene therapy; oversaw global drug development in TTR-amyloidosis, and was Global Medical Lead for hematology, specifically in hemophilia A and B, across North America, Europe and Asia, including Japan and China.  Prior to her time at Pfizer, Dr. Orfali held several clinical leadership positions, including Senior Director, Global Medical Monitor, Oncology at Wyeth Pharmaceutical Company, USA; VP Clinical Development and Medical Affairs at Artisan Pharma, Inc., USA; Vice President, Clinical Research and Medical Affairs, Aeris Therapeutics, USA;  Medical Director, CDMA,  Cubist Pharmaceuticals and Medical Director, Women’s Health Group at Boston Scientific Corporation.

 

Dr. Orfali holds a medical degree from the University of Baghdad, Baghdad, Iraq, and a Pharmaceutical Master of Business Administration from Cambridge University, Cambridge, England. She completed her Fellowship in Pediatric Oncology/Hematology at Massachusetts General Hospital and Children’s Hospital, Boston, MA and practiced medicine and conducted clinical research in medical oncology at Dana Farber Cancer research Institute.